Marijuana Internacional

Werbung:
"CBD administration is associated with decreased daytime fatigue and improved psychological well-being, according to randomized placebo-controlled data published in the journal Cannabis and Cannabinoid Research.

A team of Croatian researchers assessed the use of
CBD versus placebo on participants’ quality of life. Subjects consumed either CBD or placebo for five-week intervals."

.
 
"Nearly one in five patients with endometriosis report using cannabis to effectively manage their pain or other related symptoms, according to survey data published in the journal Archives of Gynecology and Obstetrics.

German investigators surveyed over 900 patients with endometriosis. Consistent with prior analyses, a significant percentage of respondents acknowledged using cannabis products and most said that they were highly effective at mitigating their symptoms."

.
.
 
"Patients with neuropathy, fibromyalgia, osteoarthritis, and other rheumatic conditions frequently substitute cannabis in place of prescription medications, according to survey data published in the journal Open Neurology.

Researchers affiliated with McGill University in Montreal and the University of Michigan surveyed 763 US and Canadian patients with rheumatic conditions."

.
 
"The daily topical application of hemp seed oil improves osteoarthritic knee pain, according to placebo-controlled clinical trial data published in the journal Pain Management Nursing.

Iranian investigators assessed the efficacy of
cold-pressed hemp seed oil versus either placebo or the NSAID diclofenac (aka Voltaren) in 90 patients with osteoarthritic knee pain and stiffness. Patients enrolled in the trial were between the ages of 45 and 70 years old. Study participants were assessed at baseline and again at four weeks and at eight weeks.

Researchers reported that the topical application of hemp seed oil provided therapeutic effects similar to those of diclofenac and superior to those of the placebo. Investigators reported that the oil was “safe and well tolerated.”

.
 
Werbung:
"The daily use of cannabidiol reduces symptom severity in patients at clinically high risk of suffering from psychosis, according to placebo-controlled clinical trial data published in the journal World Psychiatry.

Thirty-one patients completed the study. Subjects received 600 mg of CBD or a placebo daily for three weeks. None of the participants received any prescription medications during the trial. Patients were assessed at baseline, at seven days, and at 21 days.

Compared to the placebo group, those who received CBD had lower total CAARMS (Comprehensive Assessment of At‐Risk Mental States) scores following treatment. CBD dosing was associated with a “reduction in the severity of CHR [clinically high risk] symptoms and the distress associated with psychotic experiences,” investigators reported."

.
 
Back
Top